Nov 21, 2023 / 01:00PM GMT
Presentation
Nov 21, 2023 / 01:00PM GMT
=====================
Corporate Participants
=====================
* Christian Rommel
Bayer Aktiengesellschaft - Head of Research & Development at Pharmaceuticals Division
* Jost Reinhard
Bayer Aktiengesellschaft - Head of IR
* Stefan Oelrich
Bayer Aktiengesellschaft - Head of the Pharmaceuticals Division & Member of the Board of Management
* William N. Anderson
Bayer Aktiengesellschaft - Chairman of the Management Board & CEO
* Wolfgang U. Nickl
Bayer Aktiengesellschaft - CFO & Member of Management Board
=====================
Conference Call Participants
=====================
* Alycia Samsudin
* Charles Bentley
Jefferies LLC, Research Division - Equity Analyst
* Damien Conover
Morningstar Inc., Research Division - Sector Director and Equities Strategist
* Gunther Zechmann
Sanford C. Bernstein & Co., LLC., Research Division - Research Analyst
* Peter Verdult
Citigroup Inc.,
Bayer AG
(BUD:BAYER)
Ft
8700
-1231 (-12.4%)
Market Cap: 8.42 Tn
Enterprise Value: 21.68 Tn
PE Ratio: 0
PB Ratio: 0.59
GF Score: 50/100 Bayer AG to Share the Background and First Assessments of OCEANIC-AF Trial Presentation Transcript
Nov 21, 2023 / 01:00PM GMT
Release Date Price:
Ft13000
(+0.11%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot